Spanish for neurology clinic nurses: the patient who stopped his seizure medication because he had been seizure-free for two years and decided he was cured, the patient with Parkinson’s whose afternoon stiffness is a timing problem her nurse has never explained, and the patient whose MS fatigue the team has documented as “managing well” for three years because nobody asked what “manejando” means

Rodrigo Castillo was thirty-four years old, a warehouse worker from Stockton, and he had juvenile myoclonic epilepsy. He had been diagnosed at nineteen after a generalized tonic-clonic seizure during finals week at junior college — he had been sleep-deprived for three days, and the morning of the seizure he had woken up with his hands shaking over breakfast in a way he had written off as caffeine. He woke up in the emergency department. A week later, a neurologist explained that he had a form of epilepsy in which the brain was predisposed to seizures under conditions of sleep deprivation, stress, and alcohol — and that he would need medication.

He had been on levetiracetam since then. One thousand five hundred milligrams twice daily. He took it every morning and every night with the reliability of someone who had lost a driver’s license once and did not intend to lose it again. The last time he had had a seizure was at twenty-eight — a brief absence-like episode during a shift, reported to no one, which the neurologist attributed to a week of missed doses while he was camping without his bag.

For the past twenty-six months, nothing. No seizures. Not a morning tremor. Not a moment he questioned whether the medication was still necessary. And then, two months ago, he did question it. His cousin had told him about a friend who had been on seizure medication for years and then stopped under a doctor’s supervision because the EEG was normal and had been fine ever since. Rodrigo’s EEGs had been normal for four years. He was in the best shape of his life. He had not had a seizure in over two years.

He stopped the levetiracetam eight weeks before his annual visit. He tapered it himself over two weeks — half a pill less per dose for a week, then none. He told himself he would mention it at the visit if it came up. When the nurse asked how the medication was going, he said: “Bien. Todo normal.”

Three outpatient neurology clinic patterns that arrive without announcing themselves: Rodrigo, whose juvenile myoclonic epilepsy was controlled by levetiracetam and who stopped the medication eight weeks ago because he felt cured, and who is at significantly elevated risk for a seizure that would cost him his driver’s license and his job; Lucía Ramírez, 71, retired seamstress from Bell Gardens, whose Parkinson’s disease is being managed with carbidopa/levodopa three times daily but whose daughter brings her to every visit describing “se pone rígida como una tabla” every afternoon around three o’clock, a phenomenon that has been documented in the chart for two years as “wearing-off considered” without anyone explaining to Lucía what wearing-off means or when she is supposed to take her doses; and Consuelo Rivas, 47, school librarian from San Bernardino with relapsing-remitting MS on natalizumab, whose Modified Fatigue Impact Scale score has been above fifty at every quarterly visit for three years, and who has answered “me estoy manejando bien” when asked how she is feeling, and whose chart contains the phrase “patient denying fatigue” in every visit note, and who has never been offered an intervention for MS fatigue.

The patient who stopped his seizure medication because he had been seizure-free for two years and decided he was cured

The nurse reviewing Rodrigo’s chart before the annual visit saw the levetiracetam prescription, the normal EEG from fourteen months ago, and twenty-six months without a documented seizure. She also saw that the most recent pharmacy refill had been twelve weeks ago — for a thirty-day supply.

She walked in prepared. She started with the standard intake and then said: “¿Ha habido algún cambio en cómo está tomando el medicamento para la epilepsia — algún día que se lo saltó, alguna semana que lo dejó, o algo que lo hizo pensar que ya no lo necesitaba?”

Rodrigo: “Pues… sí. Lo dejé hace como dos meses. Me fui reduciendo solo.”

“¿Qué lo llevó a esa decisión?”

“Llevaba más de dos años sin nada. Me siento bien. El EEG estaba normal. Pensé que ya me había curado.”

The nurse wrote this down without reacting. She had heard this conversation before — not frequently, but with enough regularity to know that it was the most logical conclusion available to a patient who had only been told that the medication was working. She had never been in a room where someone explained to Rodrigo what “working” meant in the context of juvenile myoclonic epilepsy.

“Gracias por decirme esto. Lo que hizo tiene completamente sentido dado lo que usted sabía. Y quiero explicarle algo que tal vez nadie le ha dicho claramente, porque cambia bastante cómo se ve la situación.”

“Estar libre de crisis durante dos años es exactamente lo que el medicamento se supone que tiene que hacer. Eso no es suerte — es que el medicamento está funcionando. Pero hay una diferencia importante entre ‘el medicamento curó la epilepsia’ y ‘el medicamento está controlando la epilepsia.’ El tipo de epilepsia que usted tiene — la epilepsia mioclónica juvenil — no es una condición que desaparece con el tiempo. Lo que su cerebro tiene que hace que pueda tener crisis sigue ahí, igual que el primer día. Lo que el medicamento hace es actuar como un regulador que evita que esa actividad se convierta en una crisis. Cuando usted deja el medicamento, el regulador desaparece.”

Rodrigo: “¿Y qué quiere decir eso prácticamente?”

“Quiere decir que el riesgo de tener una crisis vuelve. No inmediatamente, no siempre — pero en el tipo de epilepsia que usted tiene, la probabilidad de que vuelvan las crisis después de dejar el medicamento es muy alta, incluso después de años sin ellas. Hay estudios que muestran que entre el ochenta y el noventa por ciento de los pacientes con epilepsia mioclónica juvenil tienen una recaida después de dejar el medicamento — aunque lleven años sin crisis. No es que usted haya hecho algo malo. Es que este tipo de epilepsia es de por vida en la mayoría de los casos.”

Rodrigo was quiet. He was looking at his hands.

“Hay algo más que quiero que sepa. Usted maneja al trabajo cuarenta y cinco minutos cada día.”

“Sí.”

“En California, si usted tiene una crisis — una sola — la ley exige que se reporte al Departamento de Vehículos de Motor. La licencia se suspende automáticamente por seis meses. No hay excepciones por primera vez. Seis meses sin poder conducir. Y si la crisis pasa mientras maneja, las consecuencias pueden ser mucho más serias para usted y para otros.”

Rodrigo: “Nadie me había dicho eso del DMV.”

“Entiendo. Eso es algo que deberíamos haber explicado mucho antes. Lo que quiero hacer ahora es hablar con el neurológo sobre reiniciar el medicamento hoy, si usted está de acuerdo. No necesita tomar una decisión ahora mismo — pero sí quiero que salga de aquí con la información completa.”

The nurse also reviewed the current risk factors. Rodrigo was working overnight shifts three days a week — irregular sleep, exactly the trigger that had produced his first seizure fifteen years ago. He was also under pressure at work because of a team restructuring. Two of the three triggers documented in his original assessment were currently active.

She noted in the chart: “Patient self-discontinued levetiracetam approximately eight weeks prior to visit with self-guided taper over two weeks. Reason: belief that seizure-freedom for 26 months indicated cure. Patient was not aware of JME natural history (lifelong in most cases; high relapse rate after AED withdrawal estimated at 80–90% in available literature). Patient was not aware of California mandatory reporting law (one seizure = automatic DMV notification, 6-month license suspension). Current risk factors active: irregular overnight shift sleep schedule, occupational stress reported. Disclosure obtained with open-ended phrasing (‘algo que lo hizo pensar que ya no lo necesitaba’). Education provided: JME as lifelong condition; distinction between controlled and cured; relapse rate data; driving implication. Provider briefed. Discussion re: levetiracetam reinitiation pending — patient amenable. If medication restarted, return in 4 weeks; if patient declines, scheduled for shared decision-making visit with neurologist.”

The neurologist confirmed the education, added that the EEG being normal was expected on medication and did not predict outcome off medication in JME, and offered Rodrigo the option of a supervised withdrawal trial with very close follow-up if he wanted to explore it with full information — while explaining the risk structure of that choice in concrete terms. Rodrigo chose to restart the levetiracetam that day. He said he wanted time to think about a supervised withdrawal trial once he understood what it would actually involve, but not now.

At the three-month follow-up, Rodrigo had no seizures. He had set reminders for both doses on his phone. He brought a question written on his phone that he read aloud: “¿Hay algo que pueda leer sobre si en algún momento sería seguro intentar dejar el medicamento bajo supervisión, o si eso en mi caso nunca va a ser una opción?” The nurse printed the patient-facing summary on JME and medication withdrawal from the Epilepsy Foundation’s Spanish-language resources before he left the room.

He said: “Nadie me había explicado que libre de crisis no significa curado. Me lo dijeron una vez pero nunca lo entendí así.”

The patient with Parkinson’s whose afternoon stiffness is a timing problem her nurse has never explained

Lucía Ramírez arrived with her daughter, Margarita. This had been the arrangement for all eight of Lucía’s neurology appointments in the past two years. Margarita drove, carried the medication list, and did most of the talking. Lucía sat with her hands folded in her lap and answered when addressed directly.

Margarita said, before the nurse had finished the intake: “El problema es en las tardes. Como a las tres o las cuatro, se pone rígida. Como una tabla. No puede agarrar la taza. No puede levantarse sola del sillón. Dura como una hora así. Y luego pasa.”

This had been in the chart at every visit for two years: “caregiver reports afternoon rigidity, approximately 1 hour in duration, self-resolving.” And at every visit: “wearing-off considered. Medication adjustment discussed.”

The nurse asked the question she had learned to ask first: “Lucía, ¿a qué hora tomó la pastilla esta mañana?”

“Con el desayuno. A las ocho y media.”

“¿Y la del mediodía?”

Lucía looked at Margarita. Margarita said: “A veces se la toma. A veces se le olvida. Si yo no estoy en casa al mediodía, a veces la toma a las dos. O a las tres.”

“¿Y cuándo empieza la rigidez?”

“Como a las tres o cuatro.”

The nurse understood immediately. There was no mystery. If Lucía took her morning dose at 8:30, the levodopa peak would arrive around 9:15, sustain through noon, and taper by 12:30 to 1:00. If the midday dose was delayed until 2:00 or 3:00, she was experiencing a pharmacokinetic trough of ninety minutes to two and a half hours — a period in which the plasma levodopa level was below the clinical threshold and the dopaminergic input to the basal ganglia fell sharply. The result was exactly what Margarita described: rigidity, difficulty rising, inability to grip. This was not disease progression. This was a dosing schedule problem. It had been in the chart for two years as a clinical puzzle when it was a scheduling question.

The nurse said: “Le voy a explicar cómo trabaja el medicamento en el cuerpo, porque eso va a aclarar por qué pasa lo que Margarita está describiendo en las tardes.”

“El Sinemet — el medicamento que toma tres veces al día — no trabaja igual todo el día. Después de que lo toma, tarda unos cuarenta y cinco minutos en subir al nivel donde funciona bien. Luego llega a su punto más alto, y después de tres a cuatro horas empieza a bajar. Cuando baja, el cuerpo vuelve a sentir los efectos del Parkinson — la rigidez, la lentitud, la dificultad para moverse. Eso es lo que Margarita está viendo en las tardes.”

Margarita: “¿O sea que si toma la pastilla tarde, el bajón llega antes?”

“Exactamente. Si la pastilla del mediodía se retrasa, el bajón llega más temprano y más fuerte. Lo que Lucía está viviendo en las tardes no es que el Parkinson empeoró — es que hay un período en el que el medicamento bajó y la dosis del mediodía no llegó a tiempo para cubrirlo. Eso se puede corregir con horario fijo.”

Lucía: “¿Y por qué nadie me lo había explicado así?”

The nurse did not answer that question. She moved forward.

“También hay algo sobre la comida. Las proteínas — la carne, los frijoles, el queso, los huevos — compiten con el medicamento para que el cuerpo lo absorba. Si toma la pastilla al mismo tiempo que un almuerzo con mucha proteína, menos medicamento llega al cerebro. Lo ideal es tomar el medicamento unos veinte o treinta minutos antes de comer, o una hora después. No siempre es posible, pero en el caso de Lucía, el almuerzo es cuando el medicamento más importa — así que ahí vale la pena intentarlo.”

“Lo que vamos a hacer ahora mismo es fijar un horario. No ‘cuando se acuerde’ — horas fijas. Y vamos a poner las alarmas en el teléfono antes de salir de aquí.”

She asked what time Lucía woke up, when she had breakfast, when she typically ate lunch, and when she went to bed. Together they agreed on 8:00 AM, 1:00 PM, and 6:30 PM for the three doses. The nurse set three alarms on Margarita’s phone — because Margarita’s phone was newer and she was more likely to hear it — and a backup alarm on Lucía’s phone for the noon dose only. She typed the schedule on a piece of paper in large print and gave it to both of them.

The nurse wrote in the chart: “Patient presenting with afternoon rigidity documented at every visit x2 years. Direct dose-timing review today: morning dose at 8:30 AM consistently; noon dose variable, often delayed to 2:00–3:00 PM when caregiver not home at midday. Afternoon rigidity onset 3:00–4:00 PM is pharmacokinetically consistent with levodopa trough from delayed noon dose (peak to trough approximately 3.5–4.5 hours from 8:30 AM dose). Assessment: wearing-off due to dosing-schedule irregularity rather than disease progression or dose insufficiency. Intervention: fixed dosing schedule 8:00 AM / 1:00 PM / 6:30 PM established with patient and caregiver. Alarms set on both phones before leaving room. Written schedule provided in large print. Protein-timing education: levodopa absorption competition with dietary amino acids; advised to take noon dose 20–30 min before lunch when possible. No medication dose adjustment at this time. Follow-up telephone check in 4 weeks; follow-up visit in 12 weeks.”

Four weeks later, Margarita called the clinic. The nurse who answered the phone wrote in the chart: “Caregiver call: ‘Ya no se queda rígida en las tardes. Desde que pusimos las alarmas no ha pasado.’ Patient tolerating fixed schedule well. No adverse effects reported.”

At the twelve-week follow-up, Lucía arrived without the afternoon rigidity pattern for the first time in two years. The neurologist reviewed the chart, wrote “wearing-off resolved with dose-timing correction,” and asked why the alarm strategy had not been tried at any of the previous eight visits. The nurse’s note from this visit documented the question. No one answered it.

Lucía, leaving: “Dos años así y era nada más la hora de la pastilla.”

The patient whose MS fatigue the team has documented as “managing well” for three years because nobody asked what “manejando” means

Consuelo Rivas was forty-seven years old, a school librarian from San Bernardino, and she had been living with relapsing-remitting multiple sclerosis for nine years. She was on natalizumab, her third disease-modifying therapy. The first, glatiramer acetate, she had been on for three years before two clinical relapses in sixteen months prompted a switch. The second, dimethyl fumarate, she had tolerated poorly. Natalizumab had stabilized her disease for four years. Her last confirmed relapse was three years ago — a four-week episode of right-hand numbness and fatigue that resolved with a methylprednisolone course.

At every quarterly infusion visit since then, the nurse asked: “¿Cómo se ha sentido?”

Consuelo answered: “Me estoy manejando bien.”

Or: “Voy aguantando.”

Or: “Ahí sigo.”

The chart note at each visit recorded: “Patient reports doing well. Denying fatigue, focal weakness, sensory changes, vision changes, bladder symptoms.”

The Modified Fatigue Impact Scale, completed in the waiting room on a paper form at every quarterly visit, had never been below forty-eight. At the most recent visit: fifty-two. The scoring guide attached to the form indicated that scores above thirty-eight were consistent with moderate-to-severe fatigue with functional impact. Consuelo’s scores had been in the moderate-to-severe range at every visit for three years. The scores had never been discussed with her.

The nurse at this visit was new to the MS clinic. She had been asked to cover the infusion bay for a colleague who was out. She pulled the chart before the visit and read the MFIS scores. She saw the pattern. She walked in with a different question.

“Consuelo, tengo una pregunta que quiero hacerle antes de empezar. ¿Cuándo fue la última vez que usted se sintió con toda su energía durante un día normal de trabajo?”

A pause.

“¿Con toda la energía?”

“Sí. Un día de trabajo normal, sintiéndose bien al terminar. ¿Cuándo fue la última vez?”

Consuelo thought. “No sé. Hace mucho. Antes de la recaída, tal vez. O antes. Antes del cambio de medicamento.”

“¿Y qué ha tenido que dejar de hacer — cosas que antes hacía sin problema — porque la energía no le alcanza?”

A longer pause. Consuelo looked at her hands.

“La cena del domingo para la familia. Antes cocinaba todos los domingos para mis hijos y mi mamá. Hace como un año y medio que les digo que vayan a un restaurante o que traigan algo. Me da mucha tristeza, pero para el domingo ya no me queda nada.”

She stopped, then continued.

“Tampoco manejo a Riverside para ver a mi hermana. Son cuarenta y cinco minutos. El camino de regreso me deja tan cansada que el día siguiente no sirvo. Ya casi no voy.”

“¿Y al trabajo?”

“Al trabajo sí. Pero los días que tengo cita aquí me acuesto a las siete de la noche porque el viaje me acaba. Y cuando llego aquí y me preguntan cómo estoy, digo ‘manejando bien’ porque sí estoy manejando — estoy yendo al trabajo, estoy viniendo a las citas, estoy funcionando. Pero no estoy bien.”

The nurse understood what had happened. “Manejando bien” was not “doing well.” It was “getting through.” Consuelo had been communicating the presence of a significant symptom burden at every visit for three years, using the language she had available, which did not map onto the binary the chart note captured. The team had heard “manejando bien” and documented “patient denying fatigue.” Consuelo had heard herself say “manejando bien” and believed she had described her situation. Both were true in different languages. The MFIS form, completed accurately at every visit, had been sitting in the chart as the clinical signal that neither party had read across the language gap.

“Consuelo, lo que me está describiendo es fatiga significativa — el tipo de fatiga que afecta su vida de manera real. Dejar de cocinar los domingos, ya no poder ir a Riverside, necesitar dormir a las siete los días de cita. Eso no es ‘manejando bien’ en el sentido de que el síntoma no importa — eso es manejando una carga grande.”

“La forma en que llenó el cuestionario de cansancio hoy — y cómo lo ha llenado en las últimas visitas — muestra que la fatiga es moderada a severa. Y hay cosas que podemos hacer con eso. No es un síntoma que tengamos que dejar así porque ‘así es la esclerosis.’”

Consuelo: “¿De verdad? Pensé que me ibían a decir que era parte de la enfermedad y que había que aguantarla.”

“La fatiga sí es parte de la esclerosis múltiple — pero hay opciones. La más estudiada es la amantadina — un medicamento que puede reducir la fatiga en algunos pacientes con EM. También hay evidencia sólida para el ejercicio aeróbico estructurado — no porque le falte fuerza de voluntad, sino porque el ejercicio cambia la forma en que el cerebro procesa la señal de fatiga. Y hay técnicas de manejo de energía — cómo distribuir las actividades a lo largo del día para que no llegue al trabajo con el tanque ya a la mitad. Un terapeuta ocupacional que trabaje con pacientes de EM puede enseñarle esto en una o dos sesiones.”

Consuelo: “Llevo tres años viniendo aquí y nadie me había dicho esto.”

“Lo sé. Y una parte de eso es que cuando preguntamos ‘¿cómo se siente?’ y usted dice ‘manejando bien,’ eso quedó anotado como si la fatiga no fuera un problema. No porque usted no lo dijera — sino porque ‘manejando’ se leyó de una forma que no era la que usted quería decir. Eso es algo que este equipo tiene que hacer mejor.”

The nurse wrote in the chart: “MFIS score 52 today (consistent with prior scores at all visits, range 48–56 over 12 quarters). Direct inquiry today using functional anchoring questions (‘última vez con toda su energía’ and ‘qué ha dejado de hacer’) produced disclosure of: stopped cooking Sunday family dinners (approx. 18 months ago), stopped driving 45-min round-trip to Riverside (stopped approximately 1 year ago due to post-drive exhaustion), goes to bed at 7 PM on infusion clinic days due to trip fatigue. Patient had been answering ‘me estoy manejando bien’ to intake question; patient clarifies this means ‘getting through, not doing well.’ Prior notes have documented this as ‘patient denying fatigue’ — this is a clinical documentation error reflecting language-interpretation failure, not patient reporting. Fatigue functional severity: moderate-to-severe (MFIS >38 at all visits; functional impact confirmed by direct interview today). Interventions discussed: amantadine (evidence base for MS fatigue reviewed), structured aerobic exercise (MS Fitness program referral provided), occupational therapy referral for energy conservation techniques, sleep hygiene (7 PM bedtime on clinic days as pacing response). Amantadine trial to be discussed with neurologist at this visit. Provider briefed. Follow-up in 8 weeks to assess amantadine response if initiated.”

The neurologist reviewed the chart and the nurse’s note, initiated amantadine 100 mg BID, and scheduled a follow-up at eight weeks. She also added a note to the clinic protocol: all intake questions for Spanish-speaking patients should include functional anchoring questions for fatigue (“¿qué ha tenido que dejar de hacer?”) rather than direct symptom questions, after this case.

At the eight-week follow-up: Consuelo reported that she had cooked one Sunday dinner three weeks after starting the amantadine. She had been able to drive to Riverside once. She was still tired, but the floor was higher. She said: “Creí que estaba diciendo que me afectaba. Yo dije ‘me estoy manejando’ y assumí que usted entendía que eso quería decir ‘sí me afecta, pero no puedo pedir más.’”

Vocabulary and phrases

How do I explain to a Spanish-speaking epilepsy patient that seizure-free does not mean cured?

The patient who stopped a seizure medication because they felt well has done something entirely reasonable with the information they had. Acknowledge the result before correcting the interpretation: “Estar libre de crisis durante dos años es exactamente lo que el medicamento se supone que tiene que hacer. Eso es un éxito.” Then the distinction: “Pero hay una diferencia entre ‘el medicamento curó la epilepsia’ y ‘el medicamento está controlando la epilepsia.’ Lo que su cerebro tiene que hace que pueda tener crisis sigue ahí — el medicamento actúa como un regulador. Cuando lo deja, el regulador desaparece.” The driving implication is often the most concrete: “En California, una sola crisis revoca la licencia de conducir por seis meses — automáticamente. Eso no es una posibilidad remota — es la ley.” The patient who drives forty-five minutes to work hears this differently than they hear the abstract seizure risk. Name the stakes in terms of what the patient is protecting.

How do I explain carbidopa/levodopa timing to a Spanish-speaking Parkinson’s patient?

The curve analogy: “El medicamento no trabaja igual todo el día. Sube en unos cuarenta y cinco minutos, llega a su punto más alto, y después de tres a cuatro horas empieza a bajar. Cuando baja, el cuerpo vuelve a sentir el Parkinson — rigidez, lentitud. Si la pastilla del mediodía se retrasa, ese bajón llega más temprano y más fuerte.” The protein-timing piece: “La carne, los frijoles, el queso — compiten con el medicamento para que el cuerpo lo absorba. Tomar la pastilla veinte o treinta minutos antes de comer ayuda a que llegue bien.” Do not finish this conversation without setting the alarms. Ask to see the patient’s phone (or the caregiver’s phone), set the three alarms at the agreed times before anyone leaves the room, and give a written schedule in large print. The alarm is not a suggestion. It is the intervention.

Why does “me estoy manejando bien” not mean the patient is doing well?

In Mexican Spanish, “manejando” carries the meaning of coping or enduring, not of doing well or thriving. A patient who says “me estoy manejando bien” is often communicating: I am getting through the day under a significant burden and I have adapted. She is not saying the burden is absent or manageable in a clinical sense. The two questions that distinguish managing-as-coping from managing-as-doing-well: First: “¿Cuándo fue la última vez que se sintió con toda su energía durante un día normal de trabajo?” Second: “¿Qué ha tenido que dejar de hacer que antes hacía sin problema, porque la energía no le alcanza?” The patient who answers the second question with a list of things she has stopped doing — cooking, driving, visiting family — is describing moderate-to-severe fatigue with functional impact. That is clinically actionable regardless of how she answered the direct symptom question.

Spanish vocabulary for neurology clinic nursing

Epilepsy: “epilepsia” — patients say “los ataques,” “las convulsiones,” “los nervios.” Seizure: “crisis epiléptica,” “convulsión” — patients say “el ataque,” “cuando me pegó,” “cuando me caí.” Seizure-free: “libre de crisis” — patients say “sin ataques,” “ya no me da.” Antiepileptic drug: “medicamento anticonvulsivo,” “medicamento para la epilepsia” — patients say “la pastilla para los nervios,” “la medicina para los ataques.” Levetiracetam: patients often know it as “Keppra,” “la pastilla azul.” Parkinson’s disease: “enfermedad de Parkinson” — patients say “el temblor,” “lo que me da en las manos.” Rigidity: “rigidez” — patients say “me pongo tieso,” “se me agarrota;” caregivers say “se pone como tabla.” Bradykinesia: “lentitud de movimientos” — patients say “me muevo muy despacio,” “todo me cuesta más.” Wearing off: “bajón del medicamento,” “cuando el medicamento baja” — patients say “cuando me regresa,” “cuando siento que vuelve el Parkinson.” Carbidopa/levodopa: patients often know it as “Sinemet,” “la pastilla que tomo tres veces al día.” Multiple sclerosis: “esclerosis múltiple,” “EM” — patients say “la esclerosis,” “la enfermedad que tengo en el cerebro.” MS fatigue: “fatiga de la esclerosis múltiple” — patients say “el cansancio,” “la fatiga,” “me agoto muy rápido,” or most commonly: “me estoy manejando.” Relapse: “recaída,” “brote” — patients say “cuando me volvió,” “la vez que me volvió a pegar.” Natalizumab: patients often know it as “Tysabri,” “la infusión mensual.” Managing (clinical use): “manejando,” “aguantando” — clinical meaning: enduring and coping under burden, not doing well. Do not document as “denying symptom.”

Three Spanish questions to ask at every neurology clinic visit with a Spanish-speaking patient

(1) “¿Ha habido algún cambio en cómo está tomando el medicamento para los nervios — algún día que se lo saltó, alguna semana que lo dejó, o algo que lo hizo pensar que ya no lo necesitaba?” — the question that finds Rodrigo. The standard “¿está tomando su medicamento?” is answered truthfully by a patient who restarted the day before the visit to avoid the conversation. The phrase “algo que lo hizo pensar que ya no lo necesitaba” names the reasoning without labeling it as non-adherence. (2) “¿A qué hora tomó la pastilla esta mañana? ¿Y la del mediodía? ¿Tiene su teléfono aquí para poner una alarma antes de salir?” — the question that finds the wearing-off. Ask to see the actual clock time, not “a las horas de costumbre.” Set the alarm before the patient leaves the room. This is the intervention. (3) “¿Cuándo fue la última vez que se sintió con toda su energía durante un día normal de trabajo?” followed by “¿Qué ha tenido que dejar de hacer que antes hacía sin problema, porque la energía no le alcanza?” — the two-question sequence that finds Consuelo. Do not accept “manejando” as a negative screen for fatigue. Ask about function. What a patient has stopped doing is the clinical measure of what a symptom is costing her.

Related reading: The brown-paper-bag medication review in Spanish: a 7-rule playbook from real shifts · Discharge instructions in Spanish: why the last 5 minutes of the ED visit are the most dangerous · Spanish for neurology nurses: last-known-well, NIHSS arm drift, and seizure witness history · Spanish for dermatology clinic nurses · Spanish for rheumatology clinic nurses · Spanish for pulmonology clinic nurses · Spanish for cardiology clinic nurses · How to explain a new diagnosis in Spanish · Herbal supplement interactions in Spanish: what your Spanish-speaking patients are not telling you · Practice these scenarios on ClinicaLingo · Download the free 50-phrase clinical-Spanish PDF